证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 编号：2025-006 | 投资者关系活动类 | 特定对象调研 □分析师会议 | | --- | --- | | 别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | 现场参观 | | | 其他 电话会议 | | 参与单位名称及人 | 华夏基金、嘉实基金、、前海开源基金、Dymon Asia Capital、前海海运通、 | | 员姓名 | 大家资产、大摩基金、国金证券、华源证券、国盛证券、中信证券、中邮证券、 | | | 天风证券、兴业证券、信达证券、华创证券、中信建投证券、东方财富证券、 | | | 博远基金、国任保险、东北证券、高毅资产、国泰海通、泓德基金、华盖资本、 | | | 华金证券、华西自营、华夏创新、明河投资、青骊投资、山东嘉信、上海坤阳、 | | | 上海盘京、上海勤辰、上海人寿、彤心雕珑、上海证券、尚石投资、尚诚资管、 | | | 一诺基金、太朴生命科学投资、泰信基金、英大自营、甬兴证券、招商基金、 | | | 中银基金、中信证券、浙商资管、真脉投资、中加基金、中 ...

Group 1: Company Performance - The company achieved a revenue of 2.983 billion CNY in 2024, representing a year-on-year growth of 4.53% [7] - The net profit attributable to shareholders was 312 million CNY, with a year-on-year increase of 22.60% [7] - The net profit excluding non-recurring gains and losses was 275 million CNY, showing a growth of 36.74% [7] - The net cash flow from operating activities reached 663 million CNY, up by 68.45% [7] Group 2: Market and Product Development - The company has established three research institutes focusing on medical electronics, biomedicine, and respiratory support, enhancing its R&D capabilities [2] - The self-developed ventilator has received high consumer recognition, with plans to launch a new generation of products [3] - The hearing aid segment reported a revenue of 273 million CNY in 2024, a growth of 37.86%, despite a loss of 43.25 million CNY due to new store performance [4] Group 3: Strategic Initiatives - The company aims for high-quality, sustainable development through diversified marketing strategies during promotional events [5] - Future dividend policies will focus on stable returns to shareholders while ensuring sustainable company growth [6] - The company is leveraging the "Healthy China" strategy and the aging population trend to drive demand for home medical devices [8] Group 4: Industry Outlook - The medical device industry is expected to grow due to increased health awareness and technological advancements [9] - Companies with strong R&D and operational capabilities are likely to maintain competitiveness, while those with product homogeneity face challenges [9] - The company plans to enhance its core product innovation and expand its international market presence [9]